Evaluation of equivalent efficacy of sinemet and sinemet CR in patients with Parkinson's disease applying levodopa dosage conversion formula

Clinical Neuropharmacology

Volumn 22, Issue 1, 1999, Pages 33-39

  Manyam, Bala V ^a   Hare, Theodore A ^b   Robbs, Randall ^a   Cubberley, Virginia B ^c  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c DUPONT COMPANY   (United States)

Author keywords

Controlled release carbidopa levodopa; Immediate release carbidopa levodopa; Motor fluctuations; Parkinson's disease; Sinemet

Indexed keywords

3 O METHYLDOPA; CARBIDOPA PLUS LEVODOPA; DIHYDROXYPHENYLACETIC ACID; DOPA; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0032905541     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199901000-00007     Document Type: Article

References (20)

1. Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S: Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. Neurology 1989;39:67-72.
2. Jankovic J, Schwartz K, Vander Linden C: Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in Parkinsonian patients with fluctuations. Mov Disord 1989;4:303-309.
3. LeWitt PA: Levodopa therapeutics: new treatment strategies. Neurology 1993;43:31-40.
4. Rondot P, Ziegler M, Aymard N, Teinturier A. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease. Neurology 1989;39(suppl 2):74-77.
5. Manyam BV, Shonkwiler S: Standard carbidopa-levodopa versus controlled-release carbidopa-levodopa in Parkinson's disease: a postmarket analysis. Clin Neuropharmacol 1994;17:128-137
6. Fahn S, Elton RL. and members of UPDRS Development Committee: The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden DD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Old Tappan, NJ: McMallen Health Information, 1988:153-163.
7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967:17:427-442.
8. Schwab RS, England ACJV. Projection technique for evaluating surgery in Parkinson's disease. In: Third symposium on Parkinson's disease. 1969:152-157.
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
10. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
11. Guy W, ed. ECDAU assessment manual of psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:534-537.
12. Manyam BV: Avoiding multiple venipuncture for glucose tolerance tests. Lab Med 1985;16:379.
13. Carrozza DP, Ferraro TN, Golden GT, Reyes PF, Hare TA: Partial characterization of kainic acid-induced striatal dopamine release using in vivo microdialysis. Brain Research 1991;543:69-76.
14. Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC. Clinical experience with controlled-release carbidopa/ levodopa in Parkinson's disease. Neurology 1993;43:677-680.
15. Block G, Irr J, Liss C, Nibbelink D, Reines S, and the CR FIRST Study Group: Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: a multi-center 5 year study. Eur Neurol 1997:37;23-27.
16. Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989;39(suppl 2):38-44.
17. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(suppl 2):25-38.
18. LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/levodopa (Sinemet 50/100 CR4): clinical and pharmacokinetic studies. Neurology 1989;39(suppl 2):45-53.
19. Kurma I, Bartholini G, Tissot R, Pletscher A: The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 1971;12:678-682.
20. Sharpless NS, Muenter MD, Tyce GM, Owen CA: 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-DOPA therapy of patients with Parkinson's disease. Clin Chim Acta 1972;37:359-369.